Lexicon Pharmaceuticals
LXRX

$1.69

3.05%

Market Cap: $611M

About: Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.

Employees: 285

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

0

Analysts bullish %

of 8 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

576% more call options, than puts

Call options by funds: $4.21M | Put options by funds: $622K

118% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 22

53% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 17

14% more capital invested

Capital invested by funds: $418M [Q1] → $475M (+$56.5M) [Q2]

8% more funds holding

Funds holding: 118 [Q1] → 127 (+9) [Q2]

7.52% more ownership

Funds ownership: 70.29% [Q1] → 77.82% (+7.52%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

See Fund Rankings

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$10

492%

upside

Avg. target

$10

492%

upside

High target

$10

492%

upside

8 analyst ratings

8 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Joseph Pantginis 37% 1-year accuracy 98 / 264 met price target	492%upside $10	Buy Reiterated	11 Sept 2024
HC Wainwright & Co. Joseph Pantginis 37% 1-year accuracy 98 / 264 met price target	492%upside $10	Buy Reiterated	3 Sept 2024
HC Wainwright & Co. Joseph Pantginis 37% 1-year accuracy 98 / 264 met price target	492%upside $10	Buy Reiterated	21 Aug 2024
HC Wainwright & Co. Joseph Pantginis 37% 1-year accuracy 98 / 264 met price target	492%upside $10	Buy Reiterated	13 Aug 2024
HC Wainwright & Co. Joseph Pantginis 37% 1-year accuracy 98 / 264 met price target	492%upside $10	Buy Reiterated	2 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about LXRX published over the past 30 days

Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer

THE WOODLANDS, Texas, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeff Wade, president and chief operating officer, has decided to step down to pursue new opportunities outside of Lexicon, effective September 30, 2024. A search for a new chief financial officer is ongoing.

Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer

New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes

Study results aligned with positive clinical trial outcomes for type 1 diabetes treatment with sotagliflozin

New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes

Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences

THE WOODLANDS, Texas, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lexicon management will participate in the following investor conferences taking place in September:

Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences

Zacks Investment Research

Lexicon (LXRX) Up as FDA Maintains Action Date for Zynquista

The FDA plans to hold an Advisory Committee meeting to give a recommendation for Lexicon's (LXRX) Zynquista (sotagliflozin) on Oct 31, 2024. Stock up.

Lexicon (LXRX) Up as FDA Maintains Action Date for Zynquista

Zacks Investment Research

Lexicon (LXRX) to Reprioritize Portfolio, Slash Jobs, Stock Up

Lexicon (LXRX) announces a portfolio reprioritization plan to focus on reducing operational expenses and driving the growth of the commercial portfolio. Shares rise.

Lexicon (LXRX) to Reprioritize Portfolio, Slash Jobs, Stock Up

Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio

Company to Focus on Targeted Promotion of INPEFA® in Heart Failure While Prioritizing Investment in the Potential Launch of ZYNQUISTA™

Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio

Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists

THE WOODLANDS, Texas, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that three poster presentations will be delivered during the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists being held August 9 - 12, 2024 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists

Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success

Lexicon Pharmaceuticals' launch of Inpefa continues to progress very slowly; prescriptions grew nearly 50% QoQ, but revenue is still below $2M and missing sell-side expectations. New leadership and cash reserves provide opportunities for Lexicon to improve commercial execution and drive revenue growth, and improved patient access and payer coverage are 2H'24 priorities. The company has resubmitted its application for Zynquista in Type 1 diabetes, a commercially significant opportunity, but one where regulatory and execution risk are still very present.

Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success

Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2024 Earnings Call Transcript

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q2 2024 Earnings Conference Call August 1, 2024 5:00 PM ET Company Participants Lisa DeFrancesco – Head-Investor Relations and Corporate Strategy Mike Exton – Chief Executive Officer and Director Jeff Wade – President and Chief Financial Officer Tom Garner – Senior Vice President and Chief Commercial Officer Craig Granowitz – Senior Vice President and Chief Medical Officer Alan Main – Executive Vice President, Innovation and Chemical Sciences Conference Call Participants Yasmeen Rahimi – Piper Sandler Andrew Tsai – Jefferies Joe Pantginis – H.C. Wainwright Roanna Ruiz – Leerink Partners Operator Good day and welcome to Lexicon Pharmaceuticals Second Quarter 2024 Financial Results Conference Call.

Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2024 Earnings Call Transcript

Zacks Investment Research

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Misses Revenue Estimates

Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.22 per share a year ago.

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Misses Revenue Estimates

See News Rankings